Aranidipine (INN, trade name Sapresta) is a calcium channel blocker. It is a dihydropyridine derivative with two active metabolites (M-1α and M-1β). It was developed by Maruko Seiyaku and has the formula methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate. Its main use is as a hypotensive, reducing blood pressure.[1][2]
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H20N2O7 |
Molar mass | 388.376 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
References
edit- ^ "Aranidipine". PubMed. Retrieved 23 December 2018.
- ^ Gelatsis P (1997). "To Market, to Market – 1996". In Bristol JA, Robertson DW, Doherty AM, Hagmann WK, Plattner JJ, Wong WW, Trainor GL (eds.). Annual Reports in Medicinal Chemistry. San Diego: Academic Press. p. 306. ISBN 978-0-08-058376-1.